Resource Summary Report

Generated by dkNET on Aug 18, 2026

Rabbit Anti-CD3 Monoclonal Antibody, Unconjugated, Clone SP7

RRID:AB_443425
Type: Antibody

Proper Citation

Abcam Cat# ab16669, RRID:AB_443425

Antibody Information

URL: http://antibodyregistry.org/AB_443425

Proper Citation: Abcam Cat# ab16669, RRID:AB_443425

Target Antigen: CD3

Host Organism: rabbit

Clonality: monoclonal

Comments: validation status unknown, seller recommendations provided in 2012: Immunohistochemistry; Western Blot; Immunohistochemistry-Fr, Immunohistochemistry-P, Western Blot
Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE

Antibody Name: Rabbit Anti-CD3 Monoclonal Antibody, Unconjugated, Clone SP7

Description: This monoclonal targets CD3

Target Organism: feline, simian, canine, baboon, horse, mouse, cat, human, dog

Clone ID: Clone SP7

Antibody ID: AB_443425

Vendor: Abcam

Catalog Number: ab16669

Record Creation Time: 20250820T042639+0000

Record Last Update: 20250820T185909+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development

No alerts have been found for Rabbit Anti-CD3 Monoclonal Antibody, Unconjugated, Clone SP7.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 176 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Tang R, et al. (2026) Mapping cell type-resolved transcriptomic profiles to patient survival in pancreatic cancer. Cancer cell.

Zhang SW, et al. (2026) Sensory neurons drive immune exclusion by stimulating a dense extracellular matrix in the breast cancer tumor microenvironment. Cell, 189(4), 1039.

Belanger K, et al. (2026) Cancer-Associated Fibroblasts Promote Epithelial-Mesenchymal Transition and Classical to Basal Subtype Shift in Pancreatic Cancer. Cancer research, 86(14), 3604.

Cheng Y, et al. (2026) A conserved eIF1A+ luminal cell-centered hypoxic and "cold" tumor microenvironment promotes pan-subtype prostate cancer progression. Cell reports. Medicine, 7(2), 102619.

Lin Y, et al. (2026) Robust transcriptomic hallmarks targeting intratumor heterogeneity in intrahepatic cholangiocarcinoma. Cell reports. Medicine, 7(4), 102708.

Zhou YD, et al. (2026) Tissue-specific tolerance mechanisms and lymph node co-drainage shape T cell immunity in the upper digestive system and pancreatic cancer progression. Cell reports, 45(5), 117324.

Lopez-Lago MA, et al. (2026) Loss of tumor suppressor NF2 mediates resistance to CAR T cell and anti-PD-1 therapy: Strategies to restore immunotherapy sensitivity. Med (New

York, N.Y.), 7(7), 101149.

Al-Ghazzawi K, et al. (2026) Matched sampling reveals uncoupled phenotypic plasticity during metastasis formation in uveal melanoma. iScience, 29(7), 116397.

Baisiwala S, et al. (2026) A human tumor-immune organoid model of glioblastoma. Cell reports, 45(1), 116790.

Gerlach I, et al. (2026) ActIIR inhibition improves motor outcome and preserves muscle fibers after experimental autoimmune neuritis. Acta neuropathologica communications, 14(1).

Jana S, et al. (2026) Collagen-Bearing Exosomes from Breast Cancer-Associated Fibroblasts Promote T-cell Dysfunction. Cancer research communications, 6(3), 630.

Lu M, et al. (2026) Homeostatic maturation programs drive human cDC2s into a tolerogenic state. Immunity, 59(5), 1201.

Suarez-Carmona M, et al. (2026) Harnessing lipid-driven immunometabolic pathways in omental metastases to enhance immunotherapy in patients with ovarian cancer. Signal transduction and targeted therapy, 11(1).

Shalita R, et al. (2026) Localized PD-1 CAR T therapy reprograms neuroinflammation. Cell.

Zhang W, et al. (2026) A poly(I:C)/QS-21-based in situ vaccine synergizes with anti-PD-1 therapy to overcome tumor immunoresistance. Cell reports. Medicine, 102932.

Pang Z, et al. (2026) Mapping cellular targets of covalent cancer drugs in the entire mammalian body. Cell, 189(3), 725.

Zhang Z, et al. (2026) Molecular insights into early malignant transition of hepatocellular carcinoma. Cancer cell, 44(5), 1012.

Allen NC, et al. (2026) NF-?B-activated fibroblasts orchestrate inflammaging and emergence of pro-inflammatory granzyme K+ T cells. Immunity, 59(6), 1561.

Len-Tayon K, et al. (2026) Impaired vitamin D signaling reveals neutrophils as key drivers of prostate cancer dissemination. EMBO molecular medicine, 18(5), 1967.

Sun Z, et al. (2026) Epstein-Barr Virus-Induced Upregulation of GPR183: A Potential Upstream Mechanism in IgG4-Related Ophthalmic Disease. Investigative ophthalmology & visual science, 67(8), 30.